Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ASP 1012

Next Previous
Drug Profile

ASP 1012

Alternative Names: ASP-1012; VET2-L2

Latest Information Update: 25 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator KaliVir Immunotherapeutics
  • Developer Astellas Pharma; KaliVir Immunotherapeutics
  • Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses
  • Mechanism of Action Cell death stimulants; Immunologic cytotoxicity; Interleukin 2 expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 04 Nov 2025 Astellas terminates a phase I clinical trial in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater, Combination therapy) in USA (IV) based on company's strategic decision (NCT06171178)
  • 27 Aug 2025 Phase-I clinical trials in Solid tumours in USA (IV) (KaliVir Immunotherapies pipeline, August 2025)
  • 26 Aug 2025 Discontinued - Phase-I for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (Astellas pipeline, August 2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top